PW03-017 – Combination TNF and IL-1 blockade in PAPA syndrome by unknown
MEETING ABSTRACT Open Access
PW03-017 – Combination TNF and IL-1
blockade in PAPA syndrome
P Hoffmann1*, AK Ombrello1, DL Stone1, KS Barron2, DL Kastner1
From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)
Lausanne, Switerland. 22-26 May 2013
Introduction
The dominantly inherited PAPA syndrome is caused by
mutations in PSTPIP1. It is one of the least understood
monogenic autoinflammatory diseases, both from a patho-
genic and treatment perspective. Patients often have persis-
tent symptoms refractory to biologic therapies that
necessitate prolonged exposure to high dose corticoster-
oids. Prior studies have reported increased production of
IL-1b and TNF-a by peripheral blood leukocytes. There
are Case reports documenting the efficacy of both IL-1 and
TNF-a antagonists in treating PAPA but, to date, there are
no reports of combination anti-TNF and anti-IL-1 use.
Objectives
To assess the safety and efficacy of combination TNF-a
and IL-1b agents in four patients with refractory PAPA.
Methods
We studied 4 patients; 3 adults (ages 52, 26, 18) and one
pediatric (age 16) patient. Two adults have the A230T
mutation and one has the E250Q mutation. The fourth has
a novel E257K mutation. Clinically, all 4 patients have pyo-
derma gangrenosum (PG) lesions and 3 of the 4 have
arthritis. All 4 patients failed monotherapy with anti-IL-1
and anti-TNF agents. Initial single-agent treatments and
dose ranges were: infliximab 5-10 mg/kg every 4-8 weeks,
adalimumab 20-80 mg every 7-14 days, etanercept 25-50
mg every 7 days, and anakinra 100-500 mg daily. Three out
of 4 patients required oral prednisone (15-60 mg daily) and
IV methylprednisolone in addition to a biologic. Due to
ineffective control of symptoms on single-agent treatment,
the combination of an anti-TNF and an anti-IL-1 agent
was introduced in all 4 patients. Patients with the A230T
mutation received infliximab and anakinra and patients
with E250Q and E257K received golimumab and anakinra.
Results
Four patients with PAPA syndrome were treated with
the combination of anti-TNF and anti-IL-1 agents. In
the 3 patients that required prednisone, after initiation
of combination treatment, the dose was successfully
decreased to 18-20 mg daily without requiring methyl-
prednisolone boluses. Clinically, there was a significant
decrease in frequency and severity of PG lesions and
arthritis. Inflammatory markers on single biologic agents
were ESR 57-86, CRP 29.5-140 mg/L and on combina-
tion treatment were ESR 2-40, CRP 0.62-14.1 mg/L. We
did not observe an increase in the frequency of serious
infections on combined biologics.
Conclusion
In patients with PAPA syndrome refractory to a single
biologic agent, the combination of an anti-TNF and an
anti-IL-1 agent is an effective alternative compared to
escalating corticosteroids. Although careful monitoring
is essential, in our patients, combination biologic ther-
apy has not been associated with an increase in infec-
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